NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 701–800 of 1,000
Rushing, A. W., Rushing, B. R., Hoang, K., Sanders, S., Péloponèse, J., Polakowski, N. J., & Lemasson, I. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007922 · Cited by 19
Fernandez, V. S., Cipolletti, M., Ascenzi, P., Marino, M., & Fiocchetti, M. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7870 · Cited by 19
“Conversely, NRF-2 acts as an oncogenic factor in fully malignant cells by increasing cell resistance to the augmented oxidative stress that could limit tumor progression (20, 26, 38).”
Tanshinone IIA inhibits osteosarcoma growth through modulation of AMPK-Nrf2 signaling pathway
Xie, Z., He, B., Jiang, Z., & Zhao, L. (2020) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2020.1772296 · Cited by 17
Gwon, Y., Oh, J., & Kim, J. (2020) · Applied Biological Chemistry · doi:10.1186/s13765-020-00578-y · Cited by 21
Halofuginone enhances the anti-tumor effect of ALA-PDT by suppressing NRF2 signaling in cSCC
Lv, T., Huang, J., Wu, M., Wang, H., Zeng, Q., & Wang, X. (2022) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102572 · Cited by 16
Molecular Mechanisms of Nemorosone-Induced Ferroptosis in Cancer Cells
Fernández-Acosta, R., Hassannia, B., Caroen, J., Wiernicki, B., Alvarez-Almiñaque, D., Verstraeten, B., der Eycken, J. V., Vandenabeele, P., Berghe, T. V., & Andreu, G. L. P. (2023) · Cells · doi:10.3390/cells12050735 · Cited by 18
“HMOX1 expression is co trolled by the transcription factor NRF2, which is kept in check by KEAP1-dependent degradative ubiquitination [43].”
BackgroundAzadian, R., Mohammadalipour, A., Memarzadeh, M. R., Hashemnia, M., & Aarabi, M. H. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02581-8 · Cited by 19
“Oxidative stress, on the other hand, releases Nrf2 from keap1 which, in turn, transports Nrf2 to the nucleus, causing to regulate the activation of defensive genes and induction of antioxidant enzymes such as SOD and CAT (Sporn and Liby 2012; Chang et al. 2013).”
Su, S., Yang, X., & Omiecinski, C. J. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.014 · Cited by 16
Kamai, T., Abe, H., Arai, K., Murakami, S., Sakamoto, S., Kaji, Y., & Yoshida, K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2272-7 · Cited by 16
“and premalignant tissues, in fully malignant cells Nrf2 activity provides growth advantage by increasing cancer chemoresistance and enhancing tumor cell growth, and high Nrf2 protein level is associated with poor prognosis in cancer [18].”
BackgroundBrd4 regulates the expression of essential autophagy genes and Keap1 in AML cells
Huang, M., Zhu, L., Garcia, J. S., Li, M. X., Gentles, A. J., & Mitchell, B. S. (2018) · Oncotarget · doi:10.18632/oncotarget.24432 · Cited by 16
“Somatic mutations in KEAP1 and NRF2 occur in a variety of cancer types and are important mediators of aberrant anti-oxidant responses [39, 40]; however, no such mutations have been reported to date in human leukemia cells (The Cancer Genome Atlas, TCGA, database) [41– 43].”
BackgroundUmapathy, D., Balashanmugam, P., Sireesh, D., Bhakkiyalakshmi, E., & Ramkumar, K. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.003 · Cited by 16
Wang, J., & Konishi, T. (2018) · Cancer Science · doi:10.1111/cas.13916 · Cited by 17
Li, S., Cheng, W., Li, Y., Xu, H., Han, H., Li, P., & Zhang, D.-X. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0526-0 · Cited by 17
Elshaer, M., ElManawy, A. I., Hammad, A., Namani, A., Wang, X. J., & Tang, X. (2020) · Aging · doi:10.18632/aging.103068 · Cited by 20
“Although cytoprotection by NRF2 activation is important for cancer chemoprevention in normal and pre-malignant tissues, in fully malignant cells NRF2 activity provides a growth advantage by increasing chemoresistance and enhancing tumor cell growth [14].”
BackgroundRole for Plant-Derived Antioxidants in Attenuating Cancer Cachexia
Li, W., Swiderski, K., Murphy, K. T., & Lynch, G. S. (2022) · Antioxidants · doi:10.3390/antiox11020183 · Cited by 19
“While Nrf2 has protective effects against various cancer types [44,45], some studies have suggested Nrf2 activation can have negative effects by elevating the antioxidant response that contributes to a resistance to cancer treatments [46–48].”
BackgroundNRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy
El‐Sehrawy, A. A. M. A., Al-dulaimi, A. A., Alkhathami, A. G., RenukaJyothi, S., Panigrahi, R., Pargaien, A. V., Singh, U., Husseini, A., & Alnajar, M. J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04324-3 · Cited by 19
“In these metastatic CRC tissues, Nrf2 was observed in the nucleus more readily, Keap1 expression was decreased, and there was evidence of an Nrf2 active state (Niture et al. 2010; Sporn and Liby 2012; Menegon et al. 2016).”
Yaylım, İ., Aru, M., Farooqi, A. A., Hakan, M. T., Buttari, B., Arese, M., & Saso, L. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.79 · Cited by 20
Gold-templated covalent targeting of the CysSec-dyad of thioredoxin reductase 1 in cancer cells
Skos, L., Schmidt, C., Thomas, S. R., Park, M., Geiger, V., Wenisch, D., Bonsignore, R., Favero, G. D., Mohr, T. T., Bileck, A., et al. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102072 · Cited by 18
Wang, C., Zhao, Y., Peng, Y., Chen, W., Zhu, J., Gu, C., Huo, R., Ding, L., Liu, T., Liu, T., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156417 · Cited by 16
Banella, C., Catalano, G., Travaglini, S., Divona, M., Masciarelli, S., Guerrera, G., Fazi, F., Lo‐Coco, F., Voso, M. T., & Noguera, N. I. (2019) · Cancers · doi:10.3390/cancers12010095 · Cited by 16
Zhou, W., Fang, C., Zhang, L., Wang, Q., Li, D., & Zhu, D. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.092 · Cited by 16
Sun, Y., He, L., Wang, W., Wang, T., Wan, H., Li, T., Wang, L., Gao, T., Chen, F., & Tang, L. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113617 · Cited by 17
Ward, A. O., Sala‐Newby, G. B., Ladak, S. S., Angelini, G. D., Caputo, M., Suleiman, M. S., Evans, P. C., George, S. J., & Zakkar, M. (2021) · Perfusion · doi:10.1177/02676591211012571 · Cited by 20
Papierska, K., Krajka‐Kuźniak, V., Paluszczak, J., Kleszcz, R., Skalski, M., Studzińska-Sroka, E., & Baer‐Dubowska, W. (2021) · Molecules · doi:10.3390/molecules26164787 · Cited by 16
Ravasz, D., Kacsó, G., Fodor, V., Horvath, K., Ádám‐Vizi, V., & Chinopoulos, C. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.05.002 · Cited by 16
Free heme regulates placenta growth factor through NRF2-antioxidant response signaling
Kapetanaki, M. G., Gbotosho, O. T., Sharma, D., Weidert, F. L., Ofori-Acquah, S. F., & Kato, G. J. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.08.009 · Cited by 15
Dual-protective nano-sunscreen enables high-efficient elimination of the self-derived hazards
Yu, B., Ai, K., & Lu, L. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.100493 · Cited by 16
USP44 Hypermethylation Promotes Cell Proliferation and Metastasis in Breast Cancer
Chen, X., Wu, X., & Wen, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0415 · Cited by 15
Bai, X., Zhang, Z., Zhang, M., Xu, J., Dong, K., Du, Q., Chen, L., Ma, P., & Yang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1566311 · Cited by 14
“These fi ndings indicate that A-MG holds promise as a viable approach for the treatment of DCM.”
Chen, L., Deng, Z., Xiong, Y., Liu, J., Huang, D., Wang, J., Chen, Y., Inuzuka, H., Xie, L., Chen, X., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06306 · Cited by 18
Kim, B., Kim, R., Kim, H. J., Kim, Y., Park, S. J., Lee, E. H., Kim, J., Kim, J., Choi, J. W., Park, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115433 · Cited by 14
Honey Phytochemicals: Bioactive Agents With Therapeutic Potential for Dermatological Disorders
McLoone, P., Oladejo, T. O., Talgatkyzy, K. L., & McDougall, G. J. (2024) · Phytotherapy Research · doi:10.1002/ptr.8330 · Cited by 14
“Nrf2 plays a principal role in the antioxidant cytoprotective responses in skin but is also involved inflammation and apoptosis and Nrf2 levels are over-expressed in several skin disorders, for example, skin cancer and psoriasis (Sporn and Liby 2012).”
Nilsen, B. W., Simón-Santamaría, J., Örtengren, U. T., Jensen, E., Bruun, J., Michelsen, V. B., & Sørensen, K. K. (2018) · European Journal Of Oral Sciences · doi:10.1111/eos.12559 · Cited by 13
Characterization of cancer omics and drug perturbations in panels of lung cancer cells
Suzuki, A., Onodera, K., Matsui, K., Seki, M., Esumi, H., Soga, T., Sugano, S., Kohno, T., Suzuki, Y., & Tsuchihara, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55692-9 · Cited by 17
Single nucleotide variants of succinate dehydrogenase A gene in renal cell carcinoma
Kamai, T., Higashi, S., Murakami, S., Arai, K., Namatame, T., Kijima, T., Abe, H., Jamiyan, T., Ishida, K., Shirataki, H., et al. (2021) · Cancer Science · doi:10.1111/cas.14977 · Cited by 15
The Role of NRF2/KEAP1 Pathway in Glioblastoma: Pharmacological Implications
Shahcheraghi, S. H., Salemi, F., Alam, W., Ashworth, H. C., Saso, L., Khan, H. Z., & Lotfi, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01693-0 · Cited by 15
Barekatain, R., & Klünemann, M. (2023) · Poultry Science · doi:10.1016/j.psj.2023.102656 · Cited by 15
Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor: In vitro Breast Cancer Study
Beeraka, N. M., Zhang, J., Zhao, D., Liu, J., Chinnappa, A. U., Hemanth Vikram, P. R., Shivaprakash, P., Bannimath, N., Manogaran, P., Sinelnikov, M. Y., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128261466231011114600 · Cited by 14
Zakeri, S., Rahimi, Z., Rezvani, N., Vaisi‐Raygani, A., Alibakhshi, R., Zakeri, S., & Yari, K. (2024) · BMC Medical Genomics · doi:10.1186/s12920-023-01791-6 · Cited by 17
“The mutations of Nrf2 result in the modification of the Nrf2 protein residues that interact with Keap1 causing activation of the cap’n’collar (CNC)– basic leucine zipper protein (bZIP) transcription factor [12] and leading to upregulation of Nrf2/ARE gene transcription [13, 14].”
BackgroundKarunatilleke, N. C., Brickenden, A. M., & Choy, W. (2024) · Protein Science · doi:10.1002/pro.5137 · Cited by 14
“Thus, Nrf2 signaling plays a critical role in counteracting the development of human diseases such as cancer, neurodegeneration, and cardio-vascular disorder (Satta et al., 2017; Sporn & Liby, 2012; Suzen et al., 2022; Wu et al., 2019).”
The role of redox system in metastasis formation
Cencioni, C., Comunanza, V., Middonti, E., Vallariello, E., & Bussolino, F. (2021) · Angiogenesis · doi:10.1007/s10456-021-09779-5 · Cited by 13
“Interestingly, NRF-2, the master gene of redox system, is often mutated in cancers [27] and is highly expressed in some cancer stem cell types [23].”
BackgroundBi, Z., Fu, Y. S., Wadgaonkar, P., Qiu, Y., Almutairy, B. S., Zhang, W., Seno, A., Thakur, C., & Chen, F. (2021) · Antioxidants · doi:10.3390/antiox11010077 · Cited by 13
“An attempt to use agents that activate or booster Nrf2 activation was made by some scientists as a measure of cancer chemoprevention [12].”
BackgroundAAED1 modulates proliferation and glycolysis in gastric cancer
Zhang, B., Wu, J., Cai, Y., Luo, M., Wang, B., & Gu, Y. (2018) · Oncology Reports · doi:10.3892/or.2018.6478 · Cited by 16
“Aberrancies in intracellular ROS levels were found to regulate NRF2 protein levels and NRF2-mediated antioxidant response, leading to cell proliferation and chemotherapy and radiotherapy resistance (30).”
Yuki, H., Kamai, T., Murakami, S., Higashi, S., Narimatsu, T., Kambara, T., Betsunoh, H., Abe, H., Arai, K., Shirataki, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25322 · Cited by 13
“Somatic mutations of Nrf2 have been reported in many human cancers, and tumorigenic mutations typically result in activation of Nrf2 targets, emphasizing the importance of this molecule [13].”
BackgroundHori, R., Yamaguchi, K., Sato, H., Watanabe, M., Tsutsumi, K., Iwamoto, S., Abe, M., Onodera, H., Nakamura, S., & Nakai, R. (2019) · Cancer Medicine · doi:10.1002/cam4.1949 · Cited by 15
An Overview of the Genomic Characterization of Hepatocellular Carcinoma
Yim, S. Y., & Lee, J. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s270533 · Cited by 13
Isosinensetin alleviates the injury of human bronchial epithelial cells induced by PM2.5
Zou, Y., Li, S., Li, X., Sun, Y., Ma, M., Tian, H., Wang, N., Yuan, J., & Xiao, C. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10870 · Cited by 13
“Nrf2 is a transcription factor which plays a vital role in activating antioxidant response by decreasing ROS production (26).”
BackgroundFrontiñán-Rubio, J., Llanos-González, E., García‐Carpintero, S., Peinado, J. R., Ballesteros‐Yáñez, I., Villar, M., de la Fuente, J., Pérez‐García, V. M., Pérez-Romasanta, L. A., Malumbres, M., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00734-0 · Cited by 13
Du, Y., Zhu, S., Wang, R., Chen, X., & Cai, K. (2022) · Molecules · doi:10.3390/molecules27248816 · Cited by 12
NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5
Gurri, S., Siegenthaler, B., Cangkrama, M., Restivo, G., Huber, M., Saliba, J., Dummer, R., Blank, V., Hohl, D., & Werner, S. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317761 · Cited by 13
“Loss of Nrf2 predisposes mice to different types of tumors, including skin SCCs, because of its important role in the detoxification of reactive oxygen species (ROS) and toxic chemicals (auf dem Keller et al , 2006; Xu et al , 2006; Sporn & Liby, 2012; Schmidlin et al , 2021).”
BackgroundReappraisal of the Roles of the Sonic Hedgehog Signaling Pathway in Hepatocellular Carcinoma
Jeng, K., Chang, C., Tsang, Y., Sheen, I., & Jeng, C. (2024) · Cancers · doi:10.3390/cancers16091739 · Cited by 14
Wang, Y., Wang, S., Ma, C., Qi, W., Lv, J., Zhang, M., Wang, S., Wang, R., Lu, Y., & Qiu, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-81375-1 · Cited by 14
“In cancers, Nrf2 is activated and overexpressed to prevent OS and to ensure cancer cells survival 39 .”
Li, R., Zeng, X. Y., Yang, M., Xu, X., Feng, J., Bao, L., Xue, B., Wang, X., & Huang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679816 · Cited by 20
Sabotaging of the oxidative stress response by an oncogenic noncoding RNA
Mahajan, N., Wu, H., Bennett, R. L., Troche, C., Licht, J. D., Weber, J. D., Maggi, L. B., & Tomasson, M. H. (2016) · The FASEB Journal · doi:10.1096/fj.201600654r · Cited by 13
“Our group discovered that ACA11 (scaRNA23), an orphan boxH/ACAclass small nucleolar RNA (snoRNA) encoded within the 18–19 intron of the WHSC1 gene, is cotranscriptionally overexpressed in t(4;14)-positive MM cells and may contribute to cellular transformation (5).”
BackgroundInfluentialCoating Dependent In Vitro Biocompatibility of New Fe-Si Nanoparticles
Balaș, M., Dumitrache, F. V., Badea, M. A., Fleaca, C. T., Criveanu, A., Tanasă, E., & Dinischiotu, A. (2018) · Nanomaterials · doi:10.3390/nano8070495 · Cited by 13
“This transcription factor binds to antioxidant response element (ARE), and activates defensive gene expression, thus increasing the antioxidant proteins levels and protecting against oxidative damage [88].”
BackgroundChen, X., Han, K. S., Zhang, T., Qi, G., Jiang, Z., & Hu, C. (2019) · Fish Physiology and Biochemistry · doi:10.1007/s10695-019-00729-z · Cited by 14
Heterogeneous genomic aberrations in esophageal squamous cell carcinoma: a review.
Li, R., Li, P., Xing, W., & Qiu, H. (2020) · PubMed · Cited by 14
Ullah, M. F., Usmani, S. A., Shah, A., & Abuduhier, F. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.011 · Cited by 15
Sulforaphane Protects Piglet Brains from Neonatal Hypoxic-Ischemic Injury
Wang, B., Kulikowicz, E., Lee, J. K., Koehler, R. C., & Yang, Z.-J. (2020) · Developmental Neuroscience · doi:10.1159/000511888 · Cited by 12
The prognostic value of NRF2 in solid tumor patients: a meta-analysis
Wang, L., Zhang, C., Qin, L., Xu, J., Li, X., Wang, W., Kong, L., Zhou, T., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19838 · Cited by 12
“More and more researchers have realized the “paradox” of NRF2 [7, 11, 12, 16] however, there is no comprehensive and quantitative analysis against the roles of NRF2 in carcinogenesis and cancer therapy.”
BackgroundAdverse Effects of Nrf2 in Different Organs and the Related Diseases
Jin, X., Chen, L., Yang, Y., Tan, R., & Jiang, C. (2025) · Antioxidants & Redox Signaling · doi:10.1089/ars.2024.0586 · Cited by 11
“Protein kinases such as AMP-activated protein kinase (AMPK), protein kinase C (PKC), and phosphatidylinositol-3-kinase (PI3K) enhance Nrf2 stability by phosphorylating it (Keum et al., 2006; Sporn and Liby, 2012).”
Tolbatov, I., & Marrone, A. (2026) · Biomolecules · doi:10.3390/biom16050671 · Cited by 15
“…it is a classical suppressor of ferroptosis, emerging evidence suggests that natural compounds like GH can utilize the NRF2-SLC7A11 axis to actually sensitize cells to disulfidptosis, indicating that NRF2 may play diametrically opposite roles depending on the therapeutic context [86] (Figure 6).”
Wu, Y., Yang, L., Wang, P., Braet, F., & Shieh, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010099 · Cited by 11
“In many cancers, the Nrf2-mediated transcription system is continuously activated through somatic mutations, induces various downstream antioxidant systems [85], and confers resistance to chemotherapy [86].”
BackgroundLuo, G., Kumar, H., Aldridge, K., Rieger, S., Han, E., Jiang, E., Chan, E. R., Soliman, A., Mahdi, H., & Letterio, J. J. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0409 · Cited by 16
“The literature has described many instances of chemore-sistance by NRF2 (Sporn and Liby, 2012; Wang et al., 2008), but we demonstrate that not all chemoresistance by NRF2 activation is comparable.”
Du, P., Han, A., Liu, J., Li, W., Feng, X., & Chen, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157024 · Cited by 15
Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
Mine, N., Yamamoto, S., Kufe, D. W., Hoff, D. D. V., & Kawabe, T. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0808 · Cited by 14
An Update on the Role of Nrf2 and its Activators in Diseases Associated with Oxidative Stress
Sugumar, D., Saravanan, J., Rymbai, E., & PRAVEEN, T. K. (2020) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.638 · Cited by 12
“These leads to a conclusion that the beneficial effects of Nrf2 activation depends on the organ affected, duration of inflammation, stage of the disease and injury model[68-71].”
BackgroundZhang, Q., Wei, D., Tan, M., Li, H., Morgan, M. A., & Sun, Y. (2020) · Neoplasia · doi:10.1016/j.neo.2020.03.002 · Cited by 11
“Finally, we found that while it had minor, if any, effect on the Ras-MAPK pathway, Sag transgenic expression caused significant accumulation of Nrf2, an antioxidant transcription factor [31] with a corresponding increase in its downstream target, Nqo1 (NAD(P)H:quinone oxidoreductase 1) by both immunoblotting and immun…”
BackgroundImmunohistochemical Characterisation of GLUT1, MMP3 and NRF2 in Osteosarcoma
Rutland, C. S., Cockcroft, J. M., Lothion‐Roy, J. H., Harris, A. E., Jeyapalan, J. N., Simpson, S., Alibhai, A. A., Bailey, C., Ballard-Reisch, A. C., Rizvanov, A. A., et al. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.704598 · Cited by 13
Cox15 is a novel oncogene that required for lung cancer cell proliferation
Zhang, C., Li, N., Liu, Y., Tian, Y., Song, Y., & Wang, X. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.010 · Cited by 11
Bumbaširević, U., Bojanić, N., Pljesa-Ercegovac, M. S., Zivkovic, M., Djukic, T. I., Zeković, M., Milojević, B., Kajmakovic, B. M., Janičić, A., Simic, T. P., et al. (2022) · Cancers · doi:10.3390/cancers14041068 · Cited by 11
“Notably, the perception of this molecule in carcinogenesis has changed from an anticancer molecule towards a molecule supporting cancer cell survival, even being considered as a possible anticancer target molecule [29,30].”
BackgroundNrf2 protein in melanoma progression, as a new means of treatment
Feng, Q., Xu, X., & Zhang, S. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13137 · Cited by 13
“Since Nrf2 shields healthy and malignant cells from oxidative damage, it prevents cancer from developing, but it also confers therapeutic resistance after cancer has taken hold (Sporn & Liby, 2012).”
BackgroundThe Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Mysona, B. A., Kansara, N., Zhao, J., & Bollinger, K. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-50174-1_20 · Cited by 15
“NRF2 is arguably the most important regulator of the expression of antioxidant molecules [72].”
BackgroundNeuroligin-3 protects retinal cells from H2O2-induced cell death via activation of Nrf2 signaling
Li, X., Huang, D. F., Yu, Q., Yang, J., & Yao, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.141 · Cited by 11
Cai, Y., Xu, J., Chen, M., Wang, D., Yang, Y., Manavalan, A., Wu, X., Liu, Y., & Cao, S. (2019) · Beverages · doi:10.3390/beverages6010001 · Cited by 11
“Nrf2 is also targeted for the prevention of cancer and other chronic diseases such as diabetes, where oxidative stress and inflammation contribute to pathogenesis [14].”
BackgroundZhao, Z., Liu, B., Ge, X., Li, Z., Yang, X., Zhou, Z., & Zhao, F. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737201 · Cited by 11
Mechanisms of Redox Regulation of Chemoresistance in Tumor Cells by Phenolic Antioxidants
Мартинович, Г. Г., Martinovich, I. V., Вчерашняя, А. В., Зенков, Н. К., Брониславовна, М. Е., Кандалинцева, Н. В., & Cherenkevich, S. N. (2017) · BIOPHYSICS · doi:10.1134/s000635091706015x · Cited by 11
Rastogi, A., Severance, E. G., Jacobs, H. M., Conlin, S. M., Islam, S. T., & Timme‐Laragy, A. R. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101788 · Cited by 11
Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming
Zhou, R., Li, Y.-J., Li, G., Li, Y., Luo, L., Wang, B., & Wang, L.-P. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02492-7 · Cited by 10
“Several studies have highlighted the persistent activation of NRF2 in various cancers, including liver, lung, ovarian, and gastric cancers [135].”
Exploring structural effects in a new class of NRF2 inhibitors
Hou, Z., Lockwood, L. R., Zhang, D., Occhiuto, C. J., Mo, L., Aldrich, K. E., Stoub, H., Gallo, K. A., Liby, K. T., & Odom, A. L. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00211f · Cited by 11
Self-citationMendonca, P., Kaur, S., Kirpal, B., & Soliman, K. F. A. (2024) · American Journal of Cancer Research · doi:10.62347/anxs3815 · Cited by 10
“Nrf2 was also described as a cytoprotective transcription factor with positive and negative effects on cancer [89, 90], protecting both normal and cancerous cells from oxidative damage, which means that it inhibits malignant transformation; however, once cancer is developed, it resists therapy [91].”
Nrf2 signaling in bone health: unlocking new avenues for osteoporosis management
Lavhale, M. P., Mandlik, S. K., Shinde, V. M., & Mandlik, D. S. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01985-7 · Cited by 11
“While Nrf2 activation is protective in degenerative conditions, excessive or prolonged activation can lead to reductive stress, interfere with normal cellular apoptosis, and potentially contribute to oncogenesis by facilitating the survival of premalignant cells (Sporn And Liby 2012).”
Association of variations in platinum resistance-related genes and prognosis in lung cancer patients
Zhou, Y.-K., Li, X., Yin, J., Zou, T., Wang, Z., Wang, Y., Cao, L., Chen, J., & Liu, Z. (2020) · Journal of Cancer · doi:10.7150/jca.44410 · Cited by 11
“Transcription factor NFE2L2 (nuclear factor, erythroid 2 like 2), also named NRF2, functions as an oncogene or tumor suppressor, it regulates the cellular antioxidant response and promotes cancer chemotherapy resistance, metastasis, and progression [26-28].”
BackgroundPersonalized profiles of antioxidant signaling pathway in patients with tuberculosis
Petrillo, S., Gallo, M. G., Santoro, A., Brugaletta, R., Nijhawan, P., Russo, C., Rosa, P. L., Raponi, M., Palamara, A. T., Bertini, E., et al. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.07.004 · Cited by 11
Structural basis of Nrf2 activation by flavonolignans from silymarin
Bello, M. (2022) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2022.108393 · Cited by 11
Moerland, J. A., Leal, A. S., Lockwood, B., Demireva, E. Y., Xie, H., Krieger-Burke, T., & Liby, K. T. (2023) · Antioxidants · doi:10.3390/antiox12010116 · Cited by 10
“While the dual role of Nrf2 in normal cells and established cancer cells has been well-characterized [24], less is known about the effects of Nrf2 during carcinogenesis.”
BackgroundInfluentialSelf-citationLiby, K. T. (2013) · Dose-Response · doi:10.2203/dose-response.13-018.liby · Cited by 10
Self-citationLou, Y., Zhang, Y., Li, R., Gu, P., Xiong, L., Zhong, H., Zhang, W., & Han, B. (2016) · Tumor Biology · doi:10.1007/s13277-015-4702-6 · Cited by 10
Jagannathan, L., Jose, C. C., Tanwar, V. S., Bhattacharya, S., & Cuddapah, S. (2017) · Toxicology Research · doi:10.1039/c6tx00432f · Cited by 9
Discovery of oxime-bearing naphthalene derivatives as a novel structural type of Nrf2 activators
Chang, K., Liang, F.-P., Chen, I., Yang, S., Juang, S., Wang, T., Chen, Y., & Tzeng, C. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.046 · Cited by 10
Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment
Zhou, Y., Wang, S., Guo, J., Li, C., Sui, M., Zeng, Z., Dang, H., Gu, Q., Zhu, J. Y., Cheng, Y., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.035 · Cited by 9
Nanomedicine‐Driven Modulation of Reductive Stress for Cancer Therapy
Mao, Y., Liu, X., Chu, X., Chen, F., Shi, R., Liu, Z., Wu, Y., Liu, Y., & Bu, W. (2025) · Advanced Science · doi:10.1002/advs.202501968 · Cited by 14
Structure-based drug design (SBDD)
Rakshit, G., Murtuja, S., Kumar, B. K., Murugesan, S., & Jayaprakash, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90608-1.00003-4 · Cited by 9
Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment
Ngo, H. K. C., Le, H., & Surh, Y. (2023) · Journal of Cancer Prevention · doi:10.15430/jcp.2023.28.4.131 · Cited by 11
“The fact that Nrf2 activates the expression of phase II and antioxidant enzymes to eliminate excessive electrophiles and ROS and favor the survival of normal cells would be logically extended to cancer cells [49].”
BackgroundMihailović, S., Coric, V. M., Radic, T. M., Savic-Radojevic, A. R., Matic, M. G., Dragicevic, D. P., Djokic, M., Vasic, V., Dzamic, Z., Simic, T. P., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6617969 · Cited by 9
“Although at first perceived as an anticancer molecule, some authors emphasize the role of Nrf2 in cancer cell survival and even suggest that it should be regarded as a possible target for future anticancer therapeutic approaches [9, 12, 13].”
BackgroundProfile of esophageal squamous cell carcinoma mutations in Brazilian patients
Munari, F. F., dos Santos, W., Evangelista, A. F., de Carvalho, A. C., Pastrez, P. R. A., Bugatti, D., Wohnrath, D. R., Scapulatempo‐Neto, C., Guimarães, D. P., Longatto‐Filho, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00208-7 · Cited by 10
li, J., Guo, J., Liu, K., Wang, J., Jiang, H., Zhang, M., Liu, Y., ChangLiang, S., Fu, W., Fu, W., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115037 · Cited by 10
Egas, V., Millán, E., Collado, J. A., Ramírez‐Ápan, T., Méndez-Cuesta, C. A., Muñóz, E., & Delgado, G. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.069 · Cited by 9
Chirumbolo, S., & Bjørklund, G. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.12.061 · Cited by 12
Iron, Copper, and Selenium: Cancer's Thing for Redox Bling
Terzi, E. M., & Possemato, R. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041545 · Cited by 10
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.